Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan

被引：0
|
作者：
Palshof, Jesper Andreas
Christensen, Troels Dreier
Poulsen, Tim Svendstrup
Jensen, Benny Vittrup
Linnemann, Dorte
Schou, Jakob Vasehus
Pfeiffer, Per
Yilmaz, Mette K. N.
Christensen, Ib Jarle
Hogdall, Estrid V.
Nielsen, Dorte
机构：
[1] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Oncol, Herlev, Denmark
[2] Herlev Univ Hosp, Dept Oncol, Herlev, Denmark
[3] Herlev Univ Hosp, Dept Pathol, Herlev, Denmark
[4] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Oncol, Copenhagen, Denmark
[5] Herlev Univ Hosp, Herlev, Denmark
[6] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[7] Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark
[8] Herlev Hosp, Univ Copenhagen, Dept Pathol, Herlev, Denmark
[9] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Pathol, Herlev, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15115
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome
    Vincenzi, B.
    Santini, D.
    Funaioli, C.
    Pinto, C.
    Di Fabio, F.
    Galluzzo, S.
    Silletta, M.
    Battistoni, F.
    Tonini, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome
    Vincenzi, Bruno
    Santini, Daniele
    Galluzzo, Sara
    Russo, Antonio
    Fulfaro, Fabio
    Silletta, Marianna
    Battistoni, Fabrizio
    Rocci, Laura
    Zobel, Bruno Beomonte
    Adamo, Vincenzo
    Dicuonzo, Giordano
    Tonini, Giuseppe
    CLINICAL CANCER RESEARCH, 2008, 14 (13) : 4219 - 4224
  • [23] Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study
    Buzaid, Antonio C.
    Mathias, Clarissa de Cerqueira
    Perazzo, Florencia
    Simon, Sergio D.
    Fein, Luis
    Hidalgo, Jorge
    Murad, Andre M.
    Esser, Regina
    Senger, Stefanie
    Lerzo, Guillermo
    CLINICAL COLORECTAL CANCER, 2010, 9 (05) : 282 - 289
  • [24] Epidermal Growth Factor Receptor Expression Discrepancies in Metastatic Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan-Based Chemotherapy Refractory to Irinotecan and Oxaliplatin INVITED COMMENTARY
    Chang, George J.
    DISEASES OF THE COLON & RECTUM, 2009, 52 (06) : 1152 - 1153
  • [25] Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines
    Tahara, Makoto
    Shirao, Kuniaki
    Boku, Narikazu
    Yamaguchi, Kensei
    Komatsu, Yoshito
    Inaba, Yoshitaka
    Arai, Tatsuhiro
    Mizunuma, Nobuyuki
    Satoh, Taroh
    Takiuchi, Hiroya
    Nishina, Tomohiro
    Sakata, Yuh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (11) : 762 - 769
  • [26] PHASE 2 TRIAL OF GEMCITABINE PLUS UFT IN OXALIPLATIN, IRINOTECAN AND FLUOROPYRIMIDINE-REFRACTORY COLORECTAL CANCER
    Lee, Keun-Wook
    Kim, Yu Jung
    Han, Sae-Won
    Kim, Tae-Yong
    Oh, Do-Youn
    Im, Seock-Ah
    Kim, Tae-You
    Bang, Yung-Jue
    Choi, In Sil
    Kim, Jee Hyun
    ANNALS OF ONCOLOGY, 2014, 25
  • [27] The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer
    Lelli, G.
    Carandina, I.
    Urbini, B.
    Guarino, S.
    Modonesi, C.
    Pedriali, M.
    JOURNAL OF CHEMOTHERAPY, 2007, 19 (05) : 590 - 595
  • [28] MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer
    Bernard Paule
    Vincent Castagne
    Véronique Picard
    Raphaël Saffroy
    René Adam
    Catherine Guettier
    Robert Farinotti
    Laurence Bonhomme-Faivre
    Medical Oncology, 2010, 27 : 1066 - 1072
  • [29] MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer
    Paule, Bernard
    Castagne, Vincent
    Picard, Veronique
    Saffroy, Raphael
    Adam, Rene
    Guettier, Catherine
    Farinotti, Robert
    Bonhomme-Faivre, Laurence
    MEDICAL ONCOLOGY, 2010, 27 (04) : 1066 - 1072
  • [30] Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study
    Mathias, C. de Cerqueira
    Perazzo, F.
    Simon, S.
    Fein, L.
    Hidalgo, J.
    Murad, A. M.
    Lerzo, G.
    Esser, R.
    Scheid, S.
    Buzaid, A. C.
    EJC SUPPLEMENTS, 2007, 5 (04): : 252 - 253
12345